RxDoctor Payments Data

Juan Gavalda, MD

Family Medicine · Grand Prairie, TXNPI 1992062160

Payments from drug & device makers

$272,887in general payments, 2019–2025

Across 1,141 payments — averaging $239.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$263K
  • Eli Lilly$4K
  • Novo Nordisk$1K
  • AstraZeneca$920
  • Boehringer Ingelheim$670
  • Abbott$498
  • plus $3K from 30 others

What the payments were for

  • Consulting fees$3,0001%
  • Speaking & faculty fees$240,10088%
  • Travel & lodging$18,7747%
  • Food & beverage$10,7704%
  • Education$2430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$272,887 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$3,406
Medicare patients
14
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin63$83,338
EliquisApixaban42$41,990
TrulicityDulaglutide22$41,217
MounjaroTirzepatide24$35,596
FarxigaDapagliflozin Propanediol18$18,677
TrintellixVortioxetine Hydrobromide11$14,158
Tresiba Flextouch U-200Insulin Degludec17$14,089
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$11,498
LinzessLinaclotide13$11,043
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,466
Rosuvastatin Calcium367$2,968
Atorvastatin Calcium284$2,158
Gabapentin74$1,810
Losartan Potassium168$1,471
Famotidine77$1,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$670$83,33863 claims
Lilly USA, LLCTrulicity, Mounjaro$263,303$76,81346 claims
PfizerEliquis$278$41,99042 claims
AstraZenecaFarxiga, Breztri Aerosphere$920$30,17534 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$134$14,15811 claims
AbbVieLinzess$100$11,04313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Grand Prairie

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →